文献速递消化道肿瘤与早癌炎症性肠病

靶向肿瘤相关巨噬细胞上的MS4A4A可恢复CD8+ T细胞介导的抗肿瘤免疫

Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.
PubMed 文献 · Gut · 2023-11-24

本研究探讨MS4A4A+肿瘤相关巨噬细胞(TAM)在结直肠癌免疫逃逸中的作用及靶向治疗策略。小鼠皮下或原位移植瘤模型显示,阻断MS4A4A或抗MS4A4A单抗可抑制肿瘤生长并增强免疫检查点抑制剂(ICI)疗效。机制上MS4A4A通过激活PI3K/AKT和JAK/STAT6通路促进巨噬细胞M2极化。

要点

  • MS4A4A在多种肿瘤的TAM中高表达,且与癌症患者不良临床结局相关。
  • 体内抑制MS4A4A或抗MS4A4A单抗治疗均能抑制肿瘤生长并改善ICI疗效。
  • 抗MS4A4A联合抗PD-1治疗对大型耐药肿瘤仍有效,加放疗可诱导完全消退。

核心结论

  • 靶向MS4A4A可增强ICI疗效,代表一种新的抗癌免疫治疗策略。

研究设计与样本

  • 采用小鼠皮下肿瘤或原位移植模型评估单独阻断MS4A4A或联合ICI治疗对肿瘤生长的抑制作用。
  • 通过流式细胞术和质谱流式技术评估MS4A4A阻断对肿瘤免疫微环境的影响。
  • 利用RNA测序和蛋白质印迹分析探究MS4A4A促进巨噬细胞M2极化的分子机制。

主要发现

  • MS4A4A在不同类型肿瘤中由TAM选择性表达,并与癌症患者不良临床结局相关。
  • 体内抑制MS4A4A和抗MS4A4A单抗治疗均能抑制肿瘤生长并改善ICI治疗疗效。
  • MS4A4A阻断重塑肿瘤免疫微环境,减少M2-TAM和耗竭T细胞浸润,增加效应CD8+ T细胞浸润。
  • 抗MS4A4A联合抗PD-1治疗对大型耐药肿瘤仍有效,进一步联合放疗可诱导完全消退。
  • MS4A4A通过激活PI3K/AKT通路和JAK/STAT6通路促进巨噬细胞M2极化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Checkpoint immunotherapy unleashes T-cell control of tumours but is suppressed by immunosuppressive myeloid cells. The transmembrane protein MS4A4A is selectively highly expressed in tumour-associated macrophages (TAMs). Here, we aimed to reveal the role of MS4A4A+ TAMs in regulating the immune escape of tumour cells and to develop novel therapeutic strategies targeting TAMs to enhance the efficacy of immune checkpoint inhibitor (ICI) in colorectal cancer. DESIGN: The inhibitory effect of MS4A4A blockade alone or combined with ICI treatment on tumour growth was assessed using murine subcutaneous tumour or orthotopic transplanted models. The effect of MS4A4A blockade on the tumour immune microenvironment was assessed by flow cytometry and mass cytometry. RNA sequencing and western blot analysis were used to further explore the molecular mechanism by which MS4A4A promoted macrophages M2 polarisation. RESULTS: MS4A4A is selectively expressed by TAMs in different types of tumours, and was associated with adverse clinical outcome in patients with cancer. In vivo inhibition of MS4A4A and anti-MS4A4A monoclonal antibody treatment both curb tumour growth and improve the effect of ICI therapy. MS4A4A blockade treatment reshaped the tumour immune microenvironment, resulting in reducing the infiltration of M2-TAMs and exhausted T cells, and increasing the infiltration of effector CD8+ T cells. Anti-MS4A4A plus anti-programmed cell death protein 1 (PD-1) therapy remained effective in large, treatment-resistant tumours and could induce complete regression when further combined with radiotherapy. Mechanistically, MS4A4A promoted M2 polarisation of macrophages by activating PI3K/AKT pathway and JAK/STAT6 pathway. CONCLUSION: Targeting MS4A4A could enhance the ICI efficacy and represent a new anticancer immunotherapy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Li Y, Shen Z, Chai Z, et al. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Gut. 2023. PMID: 37507218. doi:10.1136/gutjnl-2022-329147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。